Tags

Type your tag names separated by a space and hit enter

Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
Virol Sin. 2020 Dec; 35(6):713-724.VS

Abstract

Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies.

Authors+Show Affiliations

State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, China.State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, China.State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, China.State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, China.State Key Laboratory of Virology, School of Basic Medical Sciences, Wuhan University, Wuhan, 430072, China. yingwu@whu.edu.cn. Hubei Province Key Laboratory of Allergy and Immunology, Wuhan, 430072, China. yingwu@whu.edu.cn.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

33394351

Citation

Chen, Junsen, et al. "Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19." Virologica Sinica, vol. 35, no. 6, 2020, pp. 713-724.
Chen J, Huang R, Nie Y, et al. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. Virol Sin. 2020;35(6):713-724.
Chen, J., Huang, R., Nie, Y., Wen, X., & Wu, Y. (2020). Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. Virologica Sinica, 35(6), 713-724. https://doi.org/10.1007/s12250-020-00327-x
Chen J, et al. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. Virol Sin. 2020;35(6):713-724. PubMed PMID: 33394351.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19. AU - Chen,Junsen, AU - Huang,Rui, AU - Nie,Yiwen, AU - Wen,Xinyue, AU - Wu,Ying, Y1 - 2021/01/04/ PY - 2020/08/24/received PY - 2020/11/11/accepted PY - 2021/1/5/pubmed PY - 2021/2/16/medline PY - 2021/1/4/entrez KW - COVID-19 KW - Epitopes KW - S glycoprotein KW - mAbs SP - 713 EP - 724 JF - Virologica Sinica JO - Virol Sin VL - 35 IS - 6 N2 - Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world. As there is no specific drug for COVID-19, neutralizing antibodies are attracting more and more attention as one of the most effective means to combat the pandemic. Here, we introduced the etiological and serological characteristics of COVID-19, discussed the current stage of development of human monoclonal antibodies against SARS-CoV-2 and summarized the antigenic epitopes in the S glycoprotein, which may deepen the understanding of the profile of immune recognition and response against SARS-CoV-2 and provide insight for the design of effective vaccines and antibody-based therapies. SN - 1995-820X UR - https://www.unboundmedicine.com/medline/citation/33394351/Human_Monoclonal_Antibodies:_On_the_Menu_of_Targeted_Therapeutics_Against_COVID_19_ L2 - https://dx.doi.org/10.1007/s12250-020-00327-x DB - PRIME DP - Unbound Medicine ER -